论文部分内容阅读
目的探讨表柔比星(Epirubicin,EPB)膀胱灌注对预防浅表性膀胱癌(Superficial bladder cancer,SBC)术后复发及副反应方面是否优于丝裂霉素(Mitomycin,MMC)。方法将106例SBC术后患者随机分为两组,分别用EPB和MMC作膀胱灌注化疗,灌注化疗期间行血常规、肝肾功能检查。定期随访行膀胱镜或B超,评价肿瘤复发时间记录毒副反应。结果 EPB组51例,平均随访17.1个月,术后1年复发率为17.6%(9/51),MMC组55例,平均随访时间16.4个月,术后1年复发率为18.2%例(10/55),两组患者术后1年复发率差别无统计学意义(P>0.05);EPB组局部副反应发生率为58.8%(30/51),MMC组局部副反应发生率为56.4%(31/55),两组比较差别无统计学意义(P>0.05)。结论 EPB膀胱灌注在预防SBC术后复发及副反应方面并不优于与MMC。
Objective To investigate whether Epirubicin (EPB) is superior to mitomycin (MMC) in preventing postoperative recurrence and side effects of superficial bladder cancer (SBC). Methods One hundred and six patients with postoperative SBC were randomly divided into two groups. The patients were treated with EPB and MMC for urinary bladder chemotherapy respectively. Blood routine and liver and kidney function tests were performed during perfusion chemotherapy. Regular follow-up cystoscopy or B-ultrasound, evaluation of tumor recurrence time record of toxic and side effects. Results Fifty-one patients in EPB group were followed up for an average of 17.1 months. The recurrence rate was 17.6% (9/51) at 1 year after operation. The average follow-up time was 16.4 months in MMC group and 18.2% at 1 year after operation (P> 0.05). The incidence of local side-effects in the EPB group was 58.8% (30/51), and the incidence of local side-effects in the MMC group was 56.4 % (31/55), no significant difference between the two groups (P> 0.05). Conclusion EPB bladder irrigation is not superior to MMC in preventing postoperative recurrence and side effects of SBC.